Mercachem–Syncom Group announces the appointment of Dr. Luc Van Hijfte as Senior Vice President of Medicinal Chemistry

Published on

Mercachem and Syncom are pleased to announce the appointment of Dr. Luc Van Hijfte as the new Senior Vice President of Medicinal Chemistry, with effect from October 16th, 2017. Luc brings significant expertise in medicinal chemistry and drug discovery, and has more than 30 years’ experience in the pharmaceutical industry. Prior to joining the Mercachem–Syncom Group, he was CSO, Drug Discovery at NovAliX, where he was in charge of the integration of biophysical technologies and chemical sciences for rational structure-based drug discovery, with special focus on fragment-based lead generation. Previously, he was Senior Director, Head of Medicinal Chemistry EU, at Janssen Pharmaceutica, with responsibility for European-based medicinal chemistry, analytical technologies, and ADMET. During this tenure, Luc was privileged to contribute to several successful projects, with numerous programs entering into clinical development in the areas of neurosciences, oncology, and infectious diseases.

As part of the management team, Luc will be responsible for all medicinal chemistry activities at Mercachem and Syncom. Frank Leemhuis, Managing Director at Mercachem, said: “the knowledge, expertise, and experience that Luc, as a seasoned pharma executive, brings to our organization further strengthens our position as a leading service provider in drug discovery.” Luc van Hijfte said: “I have been impressed by the quality of the team and science at Mercachem and Syncom, and I am really thrilled to exploit all my expertise in drug discovery to bring the integrated drug-discovery capabilities to the next level.”


Do you have a question?

Do you want to stay updated on Syncom’s activities? Follow us on LinkedIn or contact us here.